Mirabegron

Evidensnivå: L5

Förutsagda indikationer: 0 st

---

Innehållsförteckning

1. Mirabegron
2. MIRABEGRON: Repurposing Evaluation — Insufficient Data for Full Assessment
   1. One-Sentence Summary
   2. Quick Overview
   3. Mechanism of Action
   4. Safety Considerations
   5. Conclusion and Next Steps
   6. Ansvarsfriskrivning

---

## Apotekarens bedömningsrapport

MIRABEGRON: Repurposing Evaluation — Insufficient Data for Full Assessment

One-Sentence Summary

MIRABEGRON (DB08893) is currently under evaluation for drug repurposing potential; however, no original indication data and no TxGNN predicted indications were returned in this Evidence Pack. Critical data gaps — including mechanism of action and regulatory package insert safety information — are classified as Blocking or High severity, preventing a complete evaluation at this time. A Hold decision is recommended until the gaps identified below are resolved.

---

Quick Overview

Item	Content
Original Indication	Not available in current data
Predicted New Indication	No TxGNN predictions returned
TxGNN Prediction Score	—
Evidence Level	L5 (model prediction only — no predictions available)
Sweden Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

---

Mechanism of Action

Detailed mechanism of action data is not available in this Evidence Pack (Data Gap DG002, severity: High). Without MOA information, it is not possible to assess the biological plausibility of any predicted repurposing direction or connect MIRABEGRON's pharmacological profile to a new therapeutic indication.

Remediation required: Query DrugBank API for DB08893 to retrieve MOA, pharmacodynamics, and target information before proceeding.

---

Safety Considerations

Please refer to the package insert for safety information.

Package insert data was queried on 2026-03-29 (query ID 4, status: success), but warning and contraindication fields have not yet been parsed into the Evidence Pack (Data Gap DG001, severity: Blocking). Drug–drug interaction data was queried and returned no results.

Remediation required: Download and parse the package insert PDF from the regulatory authority to extract key warnings and contraindications before advancing to safety screening Stage 1.

---

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack for MIRABEGRON contains no predicted repurposing indications, no original indication mapping, no mechanism of action, and no parsed safety data — two of which are classified as Blocking or High severity gaps that prevent any meaningful evaluation from proceeding.

To proceed, the following is needed:

• [Blocking — DG001] Parse the package insert PDF (already retrieved on 2026-03-29) to extract key warnings, contraindications, and special population guidance; this is required before Stage 1 safety screening can begin
• [High — DG002] Query DrugBank API for DB08893 to retrieve MOA, pharmacological targets, and drug category; this is required for mechanistic plausibility analysis
• [Required] Re-run the TxGNN prediction pipeline for MIRABEGRON to populate predicted_indications; the current Evidence Pack contains an empty predictions array, making repurposing candidate evaluation impossible
• [Required] Confirm original approved indications from regulatory sources (e.g., EMA, FDA, or TFDA) and populate original_indications to establish the repurposing baseline
• [Follow-up] Once predictions are available, re-trigger evidence collection (clinical trials, literature) for the top-ranked predicted indication(s)

  Ansvarsfriskrivning

Detta innehåll är endast avsett för forskningsändamål och utgör inte medicinsk rådgivning. Klinisk validering krävs före klinisk tillämpning.

---